Eicher Motors FY2026 Profit Surges to ₹5,040 Crore with Final Dividend Announced

Eicher Motors Limited has reported a strong financial performance for the fiscal year ended March 31, 2026. The company posted a standalone net profit of ₹5,040.82 crore, a significant growth compared to the previous year. Driven by steady operational performance, the Board of Directors has recommended a final dividend of ₹82 per equity share for the financial year, subject to approval by shareholders at the upcoming 44th Annual General Meeting.

Robust Financial Performance

Eicher Motors delivered strong growth in the final quarter and the full financial year 2025-26. The standalone revenue from operations for the year stood at ₹22,699.73 crore, up from ₹18,451.46 crore in the previous year. The net profit for the year reached ₹5,040.82 crore, compared to ₹4,279.26 crore in the previous fiscal, reflecting continued operational efficiency and market demand.

Dividend Recommendation

Recognizing the company’s solid financial health, the Board of Directors has recommended a final dividend of ₹82 per share for the fiscal year ended March 31, 2026. This dividend, payable on shares with a face value of ₹1 each, is subject to the approval of shareholders at the 44th Annual General Meeting. Upon approval, the dividend will be paid within 30 days.

Consolidated Results and Operational Highlights

On a consolidated basis, the Group performed even more robustly, reporting a net profit of ₹5,515.23 crore for the year. The Group’s consolidated revenue from operations for FY26 reached ₹23,407.56 crore. The Board also noted that the statutory auditors have issued an unmodified opinion on both the standalone and consolidated financial results. Furthermore, the company has provisioned ₹55.45 crore as an exceptional item related to the impact of the newly notified Labour Codes.

Source: BSE

Previous Article

Torrent Pharmaceuticals Q4 and Annual Results Highlight Strong Growth and JB Pharma Integration

Next Article

Torrent Pharmaceuticals Robust Q4 FY26 Performance Driven by JB Pharma Integration